Corey Cavanaugh, DO
Nephrology · Cleveland, OHNPI 1114345162
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,220 of the $35,375 with a category attached, or 85.4%. Travere Therapeutics, Inc. accounts for 66.1% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $25,250, more than ten times the $329 reported in 2021. Among nephrology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $680.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$23K
- Novartis$6K
- Otsuka America Pharmaceutical, Inc.$4K
- Jazz Pharmaceuticals Inc.$909
- Amgen$143
- AstraZeneca$89
- plus $34 from 1 others
What the payments were for
- Consulting fees$30,22085%
- Travel & lodging$2,7408%
- Food & beverage$2,4157%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 28 | $23,371 |
| Novartis | 7 | $6,451 |
| Otsuka America Pharmaceutical, Inc. | 5 | $4,378 |
| Jazz Pharmaceuticals Inc. | 9 | $909 |
| Amgen | 1 | $143 |
| AstraZeneca | 1 | $89 |
| Calliditas Therapeutics US Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,375 in reported general payments places this provider in the 90th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 16 | $20,533 |
| Candesartan Cilexetil | 12 | $604 |
| Valsartan | 12 | $212 |
| Amlodipine Besylate | 21 | $164 |
| Spironolactone | 15 | $107 |
| Hydrochlorothiazide | 16 | $89 |
| Lisinopril | 11 | $72 |
| Furosemide | 13 | $41 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Cleveland
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Sevag DemirjianCleveland$158K
- Elias BassilCleveland$80K
- Ali MehdiCleveland$76K
- Amitkumar PatelCleveland$70K
- Emilio PoggioCleveland$41K
- James SimonCleveland$29K
- Ziad ZakyCleveland$20K
- Nishigandha PradhanCleveland$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.